An Employer-Based Cost-Benefit Analysis of a Novel Pharmacotherapy Agent for Smoking Cessation

Authors:
  • RNRobert Nahoopii
    Robert Nahoopii
  • QSQayyim Said
    Qayyim Said
  • RDRiad Dirani
    Riad Dirani
  • DBDiana Brixner
    Diana Brixner

Abstract
An employer-based cost-benefit analysis for varenicline versus bupropion was conducted using clinical outcomes from a recently published trial. A decision tree model was developed based on the net benefit of treatment to produce a nonsmoker at 1 year. Sensitivity analyses were conducted based on quit rates with placebo and varenicline and the cost of varenicline. Estimated 12-month employer cost savings per non-smoking employee were $540.60 for varenicline, $269.80 for bupropion SR generic, $150.80 for bupropion SR brand, and $81.80 for placebo. Varenicline was more cost beneficial than placebo, which had quit rates of 16.9% or less. The quit rate with varenicline would have to be <or=16.9% to lose cost benefit over bupropion SR generic. The economic benefit of varenicline is improved over bupropion, despite the increased initial cost of varenicline.

This publication has 10 references indexed in Scilit: